Brom Rector, a 31-year-old former hedge-fund portfolio manager, is raising millions of dollars from scientists, financiers, and "crypto bros" to invest in psychedelic medicine treatments. These treatments are not yet legal, but investors are banking on their eventual approval for both medical and recreational use. This anticipated legalization is expected to trigger a significant boom in sectors ranging from biotechnology to entertainment, surpassing the growth seen in legal cannabis.
This investment trend highlights a growing interest in psychedelics as a viable medical treatment. Companies like Compass Pathways and Definium Therapeutics are showing promising results in clinical trials. For example, Definium Therapeutics recently unveiled late-stage trial data where its LSD formulation significantly outperformed a placebo in treating major depression, leading to a 50% jump in its shares to nearly $37. Analysts at Leerink Partners raised their peak sales estimate for Definium’s drug to between $1.5 billion and $2 billion.
Compass Pathways has also reported positive findings from two large studies on its psilocybin treatment, validating the potential of psychedelic medicine. Joshua Schimmer, an analyst at Cantor Fitzgerald, described this as “one of the most important waves of innovation we’re seeing today in biotech,” noting unprecedented improvements in psychiatric care. Despite the requirement for medical professionals to monitor patients for up to eight hours during treatment, analysts believe the market is large enough for multiple players.
Wall Street increasingly views psychedelic biotech firms as collaborators rather than rivals. A big clinical trial win for one company, like Definium Therapeutics, is seen as validating the entire field, helping to bring it mainstream. Leonid Timashev, an analyst at RBC Capital Markets, noted that an additional company in the space helps build infrastructure and improves adoption across the board. This collaborative environment suggests that the market for depression drugs, which historically supports multiple blockbuster products due to patients frequently switching medications, has ample room for new psychedelic treatments from companies like Compass and Definium. Johnson & Johnson's Spravato, a ketamine nasal spray, serves as a precedent, achieving $1.7 billion in sales last year after substantial groundwork to establish its use, demonstrating the potential for significant market penetration even for complex treatments.
The enthusiasm stems from the significant clinical results and the truly emerging nature of the field. After decades of stigma and scientific obstacles, attitudes towards psychedelic medicines are changing, driven by their prodigious efficacy in clinical testing. Investors anticipate that a rising tide will indeed lift all boats, as successful developments from individual companies reinforce the legitimacy and potential of the broader psychedelic medicine industry.
